S30 - Brain Cancer: From Epidemiology to Quality of Life
| Event Time: | Tuesday May 7, 2019 3:30 pm to 5:30 pm |
| Topic(s): | Neuro-oncology |
| Director(s): | |
| Description: | |
| Completion Message: | |
| CME Credits: | 2 |
| Core Competencies: |
| Start/End Time | Title | Faculty |
|---|---|---|
| 5:10 PM - 5:30 PM | Q&A Panel with Authors | Faculty |
| Speaker | Disclosure |
|---|
| Start Time | Pub. | Title | Presenter |
|---|---|---|---|
| 3:30 PM | 001 | Incidence and Natural History of H3 K27M-mutated Midline Gliomas in Adults |
Disclosure: Dr. Schreck has nothing to disclose.
|
| 3:30 PM | 002 | Absolute Lymphocyte Count in Patients with Glioblastoma Treated with Temozolomide Chemoradiation. |
Disclosure: Dr. Saeed Bamashmos has nothing to disclose.
|
| 3:30 PM | 003 | Treatment-related adverse effects in patients with brain cancer: identification of distinctive features for pseudoprogression and treatment-induced necrosis. |
Disclosure: Dr. Winter has nothing to disclose.
|
| 3:30 PM | 004 | Primary Brain and Central Nervous System Tumor Treatment and Survival in the United States, 2004-2014 |
Disclosure: Dr. Garcia has nothing to disclose.
|
| 3:30 PM | 005 | Prognostic Awareness and Illness Understanding in Patients with Malignant Glioma and their Caregivers |
Disclosure: Dr. Landay has nothing to disclose.
|
| 3:30 PM | 006 | A Non-interventional Study of Adjunctive Lacosamide Therapy in Patients With Brain Tumor-related Epilepsy |
Bjorn Steiniger Brach Disclosure: Dr. Ruda has nothing to disclose.
|
| 3:30 PM | 007 | Longer Median Overall Survival in Glioblastoma Patients from Racial and Ethnical Minority Groups |
Disclosure: Dr. Yu has nothing to disclose.
|
| 3:30 PM | 008 | Treatment-Related Decisions in Malignant Gliomas: A Feasibility Study |
Disclosure: Dr. Occhiogrosso has nothing to disclose.
|
| 3:30 PM | 009 | Impact of Travel Distance to Care Facility on Survival in Patients with Glioblastoma: A Retrospective Study Using the National Cancer Database |
Disclosure: Dr. Zhu has received research support from Tocagen, Inc, Novocure, Inc, Boston Biomedical Sumitomo Dainippon Pharma Global Oncology, Five Prime Therapeutics, Inc, Immuno-Cellular Therapeutics LTD.
|
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 7:00 AM-9:00 AM |
|---|
|
C5 -
What Do I Do Now?: Neurologic Consultations in Cancer Patients I
Jaishri Blakeley MD |
| 9:30 AM-11:30 AM |
|
C17 -
What Do I Do Now?: Neurologic Consultations in Cancer Patients II
Patrick Wen MD, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C41 -
Neuro-oncology in 2019: Navigating Current Trends
Maciej Mrugala MD, PhD, MPH, FAAN |
| 9:15 AM-12:00 PM |
|
Presidential Plenary Session
Natalia Rost MD, MPH, FAAN, FAHA |
| 11:30 AM-6:30 PM |
|
P1 -
Poster Session 1
|
| 3:30 PM-5:30 PM |
|
C69 -
The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders
Tobias Walbert MD, PhD |
| 4:45 PM-5:30 PM |
|
Neuro-oncology Section Guided Poster Tour
|
| 7:00 AM-9:00 AM |
|---|
|
C81 -
Core Principles of Brain Tumors
Nimish Mohile MD, FAAN |
| 11:30 AM-6:30 PM |
|
P2 -
Poster Session 2
|
| 1:00 PM-3:00 PM |
|
S14 -
Translational and Clinical Advances in Neuro-oncology
|
| 3:30 PM-5:30 PM |
|
C110 -
Adult and Pediatric Neuro-Oncology for the Neurohospitalist
Na Tosha Gatson MD, PhD |
| 9:15 AM-11:30 AM |
|---|
|
Clinical Trials Plenary Session
Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
| 11:30 AM-6:30 PM |
|
P3 -
Poster Session 3
|
| 3:30 PM-5:30 PM |
| 1:00 PM-3:00 PM |
|---|
|
C178 -
Therapy in Neurology I: Neurological Infectious Diseases and Neuro-oncology
Madhu Soni MD, FAAN |
| 2:00 PM-2:30 PM |
|---|
|
Choosing a Career in Neuro-oncology
Sylvia Kurz MD, PhD |